HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shinji Akamine Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muraoka, M. Articles by Nagayasu, T. Search for Related Content PubMed PubMed Citation Articles by Muraoka, M. Articles by Nagayasu, T. Related Collections Lung - cancer Minimally invasive surgery

Eur J Cardiothorac Surg 2007;32:356-361. doi:10.1016/j.ejcts.2007.04.030
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer

^a Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
^b Division of Pathology, Nagasaki University Hospital, Nagasaki, Japan

Received 24 February 2007; received in revised form 16 April 2007; accepted 18 April 2007.

^_* Corresponding author. Address: Department of Chest Surgery, Health Insurance Isahaya General Hospital, 24-1 Eishohigashi-machi, Iasahaya-city, Nagasaki 854-8501, Japan. Tel.: +81 957 22 1380; fax: +81 957 22 1184. (Email: mmuraoka{at}lucky.odn.ne.jp).

Objective: It is controversial whether a systematic mediastinal lymph node dissection (MLND) needs to be performed in all patients with stage I lung cancer. The present study was done to examine the new sentinel lymph nodes hypothesis based on the lobe of the primary tumor. Methods: In our first study, the lymph node (LN) metastases were assessed in 291 stage I non-small cell lung cancer (NSCLC) patients who had a major lung resection with a systematic mediastinal lymph node dissection. We evaluated the validity of using our new sentinel lymph nodes method based on the lobe of the primary tumor as follows: the pretracheal (#3), tracheobronchial (#4), and hilar nodes (#10) for right upper lobe tumors; #4, subcarinal (#7), and #10 for middle lobe tumors; the subaortic (#5), paraaortic (#6), and #10 for left upper lobe tumors; and the #7, #10, and interlobar nodes (#11) for tumors in either lower lobes. In the second study, we performed a lobectomy with new sentinel node sampling in 64 patients with preoperative complications. If all of the sampling nodes showed no metastases on frozen section diagnosis, systematic node dissections were not performed. Results: Six of 291 patients in the first study had skip metastases that did not involve the new sentinel nodes; 5 of the 6 patients had macroscopic pleural invasion. Thus, we defined pleural invasion as an exclusion criterion for the second study. In the second study, the median follow-up time was 39 months. Metastatic lymph nodes were detected in 11 of 64 patients. Fifty-three patients (83%) had no metastasis in the sampled nodes, and, therefore, a mediastinal lymph node dissection was not done. The morbidity rate in the sampling group was 36%, and there was no mortality. In the sampling group, local recurrences were observed in two patients, distant metastases in eight, and carcinomatous pleuritis in one; the overall 5-year survival rate was 82%. Conclusions: We found that it is possible to perform a less invasive lymphadenectomy for patients with stage I lung cancer using intra-operative sampling of new sentinel lymph nodes.

Key Words: Lung cancer • Diagnosis and staging • Lung cancer surgery • Lymph nodes • Mediastinal lymph nodes

This article has been cited by other articles:

				A. Watanabe, T. Mishina, S. Ohori, T. Koyanagi, S. Nakashima, T. Mawatari, Y. Kurimoto, and T. Higami Is video-assisted thoracoscopic surgery a feasible approach for clinical N0 and postoperatively pathological N2 non-small cell lung cancer? Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 812 - 818. [Abstract] [Full Text] [PDF]

				M. Muraoka Reply to Ismail Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 949 - 950. [Full Text] [PDF]

				M. F. Ismail Sentinel node sampling in stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 948 - 949. [Full Text] [PDF]